Plant-derived anti-inflammatory compounds: Hopes and disappointments regarding the translation of preclinical knowledge into clinical progress

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Fürst, Robert ^a   Zündorf, Ilse ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; COLCHICINE; CURCUMIN; EPIGALLOCATECHIN GALLATE; QUERCETIN; RESVERATROL; ANTIINFLAMMATORY AGENT; CATECHIN; IMAZAPYR; IMIDAZOLE DERIVATIVE; NICOTINIC ACID; STILBENE DERIVATIVE;

ACNE VULGARIS; ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; BIOAVAILABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONDYLOMA ACUMINATUM; FAMILIAL MEDITERRANEAN FEVER; FANCONI ANEMIA; GOUT; HEART ATRIUM FIBRILLATION; HUMAN; IDIOPATHIC DISEASE; MEDICINAL PLANT; META ANALYSIS (TOPIC); NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; PERICARDITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTPERICARDIOTOMY SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RHINITIS; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS; ANALOGS AND DERIVATIVES; ANIMAL; INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CAPSAICIN; CATECHIN; COLCHICINE; CURCUMIN; HUMANS; IMIDAZOLES; INFLAMMATION; NIACIN; STILBENES;

EID: 84902130498     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/146832     Document Type: Review

References (101)

1. Scrivo R., Vasile M., Bartosiewicz I., Valesini G., Inflammation as "common soil" of the multifactorial diseases. Autoimmunity Reviews 2011 10 7 369 374 2-s2.0-79955100645 10.1016/j.autrev.2010.12.006
2. Bellik Y., Boukraa L., Alzahrani H. A., Bakhotmah B. A., Abdellah F., Hammoudi S. M., Iguer-Ouada M., Molecular mechanism underlying anti-inflammatory and anti-allergic activities of phytochemicals: an update. Molecules 2012 18 1 322 353 2-s2.0-84878743206
3. Calixto J. B., Campos M. M., Otuki M. F., Santos A. R., Anti-inflammatory compounds of plant origin. Part II. Modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Medica 2004 70 2 93 103 2-s2.0-1542344495 10.1055/s-2004-815483
4. Calixto J. B., Otuki M. F., Santos A. R., Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor B (NF- B). Planta Medica 2003 69 11 973 983 2-s2.0-0346059349 10.1055/s-2003-45141
5. Leiherer A., Mundlein A., Drexel H., Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascular Pharmacology 2013 58 1-2 3 20 2-s2.0-84871717518 10.1016/j.vph.2012.09.002
6. Orlikova B., Legrand N., Panning J., Dicato M., Diederich M., Anti-inflammatory and anticancer drugs from nature. Cancer Treatment and Research 2014 159 123 143
7. Sultana N., Saify Z. S., Naturally occurring and synthetic agents as potential anti-inflammatory and immunomodulants. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2012 11 1 3 19
8. Epstein J., Sanderson I. R., MacDonald T. T., Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. British Journal of Nutrition 2010 103 11 1545 1557 2-s2.0-77953615306 10.1017/S0007114509993667
9. 2 cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004 25 9 1671 1679 2-s2.0-4544236324 10.1093/carcin/bgh165
10. Kim G.-Y., Kim K.-H., Lee S.-H., Yoon M.-S., Lee H.-J., Moon D.-O., Lee C.-M., Ahn S.-C., Park Y. C., Park Y.-M., Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF- B as potential targets. The Journal of Immunology 2005 174 12 8116 8124 2-s2.0-20444402292
11. Shah V. O., Ferguson J. E., Hunsaker L. A., Deck L. M., Jagt D. L. V., Natural products inhibit LPS-induced activation of pro-inflammatory cytokines in peripheral blood mononuclear cells. Natural Product Research 2010 24 12 1177 1188 2-s2.0-77954095458 10.1080/14786410903112680
12. Kumar A., Dhawan S., Hardegen N. J., Aggarwal B. B., Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)- mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor- B activation. Biochemical Pharmacology 1998 55 6 775 783 2-s2.0-0032520716 10.1016/S0006-2952(97)00557-1
13. Gupta S. C., Patchva S., Aggarwal B. B., Therapeutic roles of curcumin: lessons learned from clinical trials. The AAPS Journal 2013 15 1 195 218 2-s2.0-84871971567 10.1208/s12248-012-9432-8
14. Kumar S., Ahuja V., Sankar M. J., Kumar A., Moss A. C., Curcumin for maintenance of remission in ulcerative colitis. The Cochrane Database of Systematic Reviews 2012 10 CD008424 2-s2.0-84871895391
15. Anand P., Kunnumakkara A. B., Newman R. A., Aggarwal B. B., Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics 2007 4 6 807 818 2-s2.0-37549051274 10.1021/mp700113r
16. Bhattacharyya B., Panda D., Gupta S., Banerjee M., Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Medicinal Research Reviews 2008 28 1 155 183 2-s2.0-37249020371 10.1002/med.20097
17. Molad Y., Update on colchicine and its mechanism of action. Current Rheumatology Reports 2002 4 3 252 256 2-s2.0-0036615827
18. Nuki G., Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Current Rheumatology Reports 2008 10 3 218 227 2-s2.0-51449124322 10.1007/s11926-008-0036-3
19. Stanton R. A., Gernert K. M., Nettles J. H., Aneja R., Drugs that target dynamic microtubules: a new molecular perspective. Medicinal Research Reviews 2011 31 3 443 481 2-s2.0-79953299183 10.1002/med.20242
20. Borisy G. G., Taylor E. W., The mechanism of action of colchicine. Colchicine binding to sea urchin eggs and the mitotic apparatus. The Journal of Cell Biology 1967 34 2 535 548 2-s2.0-0014118455
21. Borisy G. G., Taylor E. W., The mechanism of action of colchicine. Binding of colchincine-3H to cellular protein. The Journal of Cell Biology 1967 34 2 525 533 2-s2.0-0014117442
22. Imazio M., Bobbio M., Cecchi E., Demarie D., Demichelis B., Pomari F., Moratti M., Gaschino G., Giammaria M., Ghisio A., Belli R., Trinchero R., Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005 112 13 2012 2016 2-s2.0-25444478136 10.1161/CIRCULATIONAHA.105.542738
23. Imazio M., Brucato A., Cemin R., A randomized trial of colchicine for acute pericarditis. The New England Journal of Medicine 2013 369 16 1522 1528 10.1056/NEJMoa1208536
24. Imazio M., Bobbio M., Cecchi E., Demarie D., Pomari F., Moratti M., Ghisio A., Belli R., Trinchero R., Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COLchicine for REcurrent pericarditis) trial. Archives of Internal Medicine 2005 165 17 1987 1991 2-s2.0-25444510637 10.1001/archinte.165.17.1987
25. Imazio M., Brucato A., Cemin R., Ferrua S., Belli R., Maestroni S., Trinchero R., Spodick D. H., Adler Y., Colchicine for recurrent pericarditis (CORP): a randomized trial. Annals of Internal Medicine 2011 155 7 409 414 2-s2.0-80053504821
26. Deftereos S., Giannopoulos G., Kossyvakis C., Efremidis M., Panagopoulou V., Kaoukis A., Raisakis K., Bouras G., Angelidis C., Theodorakis A., Driva M., Doudoumis K., Pyrgakis V., Stefanadis C., Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. Journal of the American College of Cardiology 2012 60 18 1790 1796 2-s2.0-84867890410 10.1016/j.jacc.2012.07.031
27. Imazio M., Trinchero R., Brucato A., Rovere M. E., Gandino A., Cemin R., Ferrua S., Maestroni S., Zingarelli E., Barosi A., Simon C., Sansone F., Patrini D., Vitali E., Ferrazzi P., Spodick D. H., Adler Y., COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. European Heart Journal 2010 31 22 2749 2754 2-s2.0-77958548721 10.1093/eurheartj/ehq319
28. Campagna M., Rivas C., Antiviral activity of resveratrol. Biochemical Society Transactions 2010 38, part 1 50 53 2-s2.0-76449120603 10.1042/BST0380050
29. de la Lastra C. A., Villegas I., Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Molecular Nutrition & Food Research 2005 49 5 405 430 2-s2.0-20344407841 10.1002/mnfr.200500022
30. Frombaum M., le Clanche S., Bonnefont-Rousselot D., Borderie D., Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and · NO bioavailability: potential benefits to cardiovascular diseases. Biochimie 2012 94 2 269 276 2-s2.0-84855848241 10.1016/j.biochi.2011. 11.001
31. Fulda S., Regulation of cell death and survival by resveratrol: implications for cancer therapy. Anti-Cancer Agents in Medicinal Chemistry 2012 12 8 874 879 2-s2.0-84866416684 10.2174/187152012802650129
32. Gescher A., Steward W. P., Brown K., Resveratrol in the management of human cancer: how strong is the clinical evidence? Annals of the New York Academy of Sciences 2013 1290 1 12 20 2-s2.0-84880344982 10.1111/nyas.12205
33. Goswami S. K., Das D. K., Resveratrol and chemoprevention. Cancer Letters 2009 284 1 1 6 2-s2.0-69049109766 10.1016/j.canlet.2009.01.041
34. Kovacic P., Somanathan R., Multifaceted approach to resveratrol bioactivity: focus on antioxidant action, cell signaling and safety. Oxidative Medicine and Cellular Longevity 2010 3 2 86 100 2-s2.0-77953704491 10.4161/oxim.3.2.11147
35. Ndiaye M., Kumar R., Ahmad N., Resveratrol in cancer management: where are we and where we go from here? Annals of the New York Academy of Sciences 2011 1215 1 144 149 2-s2.0-78851469731 10.1111/j.1749-6632.2010.05851.x
36. Scott E., Steward W. P., Gescher A. J., Brown K., Resveratrol in human cancer chemoprevention-choosing the "right" dose. Molecular Nutrition & Food Research 2012 56 1 7 13 2-s2.0-84855334376 10.1002/mnfr.201100400
37. Svajger U., Jeras M., Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. International Reviews of Immunology 2012 31 3 202 222 2-s2.0-84862110941 10.3109/08830185.2012.665108
38. Amri A., Chaumeil J. C., Sfar S., Charrueau C., Administration of resveratrol: what formulation solutions to bioavailability limitations? Journal of Controlled Release 2012 158 2 182 193 2-s2.0-84858709095 10.1016/j.jconrel. 2011.09.083
39. Augustin M. A., Sanguansri L., Lockett T., Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Annals of the New York Academy of Sciences 2013 1290 1 107 112 2-s2.0-84880367593 10.1111/nyas.12130
40. Neves A. R., Lucio M., Lima J. L., Reis S., Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Current Medicinal Chemistry 2012 19 11 1663 1681 2-s2.0-84860540855 10.2174/092986712799945085
41. Santos A. C., Veiga F., Ribeiro A. J., New delivery systems to improve the bioavailability of resveratrol. Expert Opinion on Drug Delivery 2011 8 8 973 990 2-s2.0-79960768800 10.1517/17425247.2011.581655
42. Walle T., Bioavailability of resveratrol. Annals of the New York Academy of Sciences 2011 1215 1 9 15 2-s2.0-78851469101 10.1111/j.1749-6632.2010.05842.x
43. Wenzel E., Somoza V., Metabolism and bioavailability of trans-resveratrol. Molecular Nutrition & Food Research 2005 49 5 472 481 2-s2.0-20344364428 10.1002/mnfr.200500010
44. Kundu J. K., Shin Y. K., Surh Y.-J., Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF- B and AP-1 as prime targets. Biochemical Pharmacology 2006 72 11 1506 1515 2-s2.0-33750494955 10.1016/j.bcp.2006.08.005
45. Surh Y.-J., Chun K.-S., Cha H.-H., Han S. S., Keum Y.-S., Park K.-K., Lee S. S., Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF- B activation. Mutation Research 2001 480-481 243 268 2-s2.0-0035451363
46. Chung S., Yao H., Caito S., Hwang J.-W., Arunachalam G., Rahman I., Regulation of SIRT1 in cellular functions: role of polyphenols. Archives of Biochemistry and Biophysics 2010 501 1 79 90 2-s2.0-77956176874 10.1016/j.abb.2010.05.003
47. Knutson M. D., Leeuwenburgh C., Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutrition Reviews 2008 66 10 591 596 2-s2.0-52649144195 10.1111/j.1753-4887.2008.00109.x
48. Nakata R., Takahashi S., Inoue H., Recent advances in the study on resveratrol. Biological & Pharmaceutical Bulletin 2012 35 3 273 279 2-s2.0-84857831235 10.1248/bpb.35.273
49. Schmitt C. A., Dirsch V. M., Modulation of endothelial nitric oxide by plant-derived products. Nitric Oxide 2009 21 2 77 91 2-s2.0-68249109183 10.1016/j.niox.2009.05.006
50. Bakker G. C., van Erk M. J., Pellis L., Wopereis S., Rubingh C. M., Cnubben N. H. P., Kooistra T., Van Ommen B., Hendriks H. F. J., An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach. The American Journal of Clinical Nutrition 2010 91 4 1044 1059 2-s2.0-77950493668 10.3945/ajcn.2009. 28822
51. Bo S., Ciccone G., Castiglione A., Gambino R., de Michieli F., Villois P., Durazzo M., Cavallo-Perin P., Cassader M., Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Current Medicinal Chemistry 2013 20 10 1323 1331 2-s2.0-84876966216 10.2174/0929867311320100009
52. Militaru C., Donoiu I., Craciun A., Scorei I. D., Bulearca A. M., Scorei R. I., Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 2013 29 1 178 183 2-s2.0-84870851275 10.1016/j.nut.2012.07.006
53. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yáñez- Gascón M. J., García-Almagro F. J., Ruiz-Ros J. A., García-Conesa M. T., Tomás-Barberán F. A., Espín J. C., One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. The American Journal of Cardiology 2012 110 3 356 363 2-s2.0-84863980958 10.1016/j.amjcard.2012.03.030
54. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yáñez- Gascón M. J., García-Almagro F. J., Ruiz-Ros J. A., Tomás-Barberán F. A., García-Conesa M. T., Espín J. C., Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovascular Drugs and Therapy 2013 27 1 37 48 2-s2.0-84873060656 10.1007/s10557-012-6427-8
55. Tome-Carneiro J., Larrosa M., Yanez-Gascon M. J., Dávalos A., Gil-Zamorano J., Gonzálvez M., García-Almagro F. J., Ruiz Ros J. A., Tomás-Barberán F. A., Espín J. C., García-Conesa M.-T., One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacological Research 2013 72 69 82 2-s2.0-84877002108 10.1016/j.phrs.2013.03.011
56. Caterina M. J., Schumacher M. A., Tominaga M., Rosen T. A., Levine J. D., Julius D., The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997 389 6653 816 824 2-s2.0-0030777012 10.1038/39807
57. O'Neill J., Brock C., Olesen A. E., Andresen T., Nilsson M., Dickenson A. H., Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacological Reviews 2012 64 4 939 971 2-s2.0-84867095636 10.1124/pr.112.006163
58. Haanpaa M., Treede R.-D., Capsaicin for neuropathic pain: linking traditional medicine and molecular biology. European Neurology 2012 68 5 264 275 2-s2.0-84866953951 10.1159/000339944
59. Joe B., Rao U. J., Lokesh B. R., Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Molecular and Cellular Biochemistry 1997 169 1-2 125 134 2-s2.0-0031056998 10.1023/A:1006877928703
60. Park J.-S., Choi M.-A., Kim B.-S., Han I.-S., Kurata T., Yu R., Capsaicin protects against ethanol-induced oxidative injury in the gastric mucosa of rats. Life Sciences 2000 67 25 3087 3093 2-s2.0-0034634270
61. Kim C.-S., Kawada T., Kim B.-S., Han I.-S., Choe S.-Y., Kurata T., Yu R., Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS-stimulated peritoneal macrophages. Cellular Signalling 2003 15 3 299 306 2-s2.0-0037346879 10.1016/S0898-6568(02)00086-4
62. Cameron M., Chrubasik S., Topical herbal therapies for treating osteoarthritis. The Cochrane Database of Systematic Reviews 2013 5 CD010538
63. de Silva V., El-Metwally A., Ernst E., Lewith G., Macfarlane G. J., Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology 2011 50 5 911 920 2-s2.0-79955128316 10.1093/rheumatology/keq379
64. Cameron M., Gagnier J. J., Little C. V., Parsons T. J., Blümle A., Chrubasik S., Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part 1: osteoarthritis. Phytotherapy Research 2009 23 11 1497 1515 2-s2.0-70350451836 10.1002/ptr.3007
65. Singh B. N., Shankar S., Srivastava R. K., Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochemical Pharmacology 2011 82 12 1807 1821 2-s2.0-80555123045 10.1016/j.bcp.2011.07.093
66. Domingo D. S., Camouse M. M., Hsia A. H., Matsui M., Maes D., Ward N. L., Cooper K. D., Baron E. D., Anti-angiogenic effects of epigallocatechin-3- gallate in human skin. International Journal of Clinical and Experimental Pathology 2010 3 7 705 709 2-s2.0-77956019858
67. Riegsecker S., Wiczynski D., Kaplan M. J., Ahmed S., Potential benefits of green tea polyphenol EGCG in the prevention and treatment of vascular inflammation in rheumatoid arthritis. Life Sciences 2013 93 8 307 312 2-s2.0-84883217899 10.1016/j.lfs.2013.07.006
68. Steinmann J., Buer J., Pietschmann T., Steinmann E., Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. British Journal of Pharmacology 2013 168 5 1059 1073 2-s2.0-84874284327 10.1111/bph.12009
69. Yang C. S., Wang H., Li G. X., Yang Z., Guan F., Jin H., Cancer prevention by tea: evidence from laboratory studies. Pharmacological Research 2011 64 2 113 122 2-s2.0-79959556771 10.1016/j.phrs.2011.03.001
70. Chen L., Zhang H.-Y., Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate. Molecules 2007 12 5 946 957 2-s2.0-34249884856 10.3390/12050946
71. Nam N.-H., Naturally occurring NF- B inhibitors. Mini-Reviews in Medicinal Chemistry 2006 6 8 945 951 2-s2.0-33746862576 10.2174/ 138955706777934937
72. Khan N., Afaq F., Saleem M., Ahmad N., Mukhtar H., Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Research 2006 66 5 2500 2505 2-s2.0-33645094927 10.1158/0008-5472.CAN-05- 3636
73. Yang H., Landis-Piwowar K., Chan T. H., Dou Q. P., Green tea polyphenols as proteasome inhibitors: implication in chemoprevention. Current Cancer Drug Targets 2011 11 3 296 306 2-s2.0-79951710144 10.2174/156800911794519743
74. Adachi S., Nagao T., Ingolfsson H. I., Maxfield F. R., Andersen O. S., Kopelovich L., Weinstein I. B., The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Research 2007 67 13 6493 6501 2-s2.0-34447129573 10.1158/0008-5472.CAN-07-0411
75. Masuda M., Wakasaki T., Toh S., Shimizu M., Adachi S., Chemoprevention of head and neck cancer by green tea extract: EGCG-the role of EGFR signaling and "lipid raft'. Journal of Oncology 2011 2011 7 2-s2.0-79952240835 10.1155/2011/540148 540148
76. Patra S. K., Rizzi F., Silva A., Rugina D. O., Bettuzzi S., Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts. Journal of Physiology and Pharmacology 2008 59 supplement 9 217 235 2-s2.0-64049093215
77. Bandele O. J., Osheroff N., (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. Chemical Research in Toxicology 2008 21 4 936 943 2-s2.0-43149124005 10.1021/tx700434v
78. Lee W. J., Shim J.-Y., Zhu B. T., Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Molecular Pharmacology 2005 68 4 1018 1030 2-s2.0-25144507259 10.1124/mol.104.008367
79. Sadava D., Whitlock E., Kane S. E., The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochemical and Biophysical Research Communications 2007 360 1 233 237 2-s2.0-34347251957 10.1016/j.bbrc.2007.06.030
80. Basu A., Du M., Sanchez K., Leyva M. J., Betts N. M., Blevins S., Wu M., Aston C. E., Lyons T. J., Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition 2011 27 2 206 213 2-s2.0-78650825302 10.1016/j.nut.2010.01.015
81. Yoon J. Y., Kwon H. H., Min S. U., Thiboutot D. M., Suh D. H., Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. The Journal of Investigative Dermatology 2013 133 2 429 440 2-s2.0-84872608286 10.1038/jid.2012.292
82. Bischoff S. C., Quercetin: potentials in the prevention and therapy of disease. Current Opinion in Clinical Nutrition and Metabolic Care 2008 11 6 733 740 2-s2.0-55149104161 10.1097/MCO.0b013e32831394b8
83. Chirumbolo S., The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflammation & Allergy Drug Targets 2010 9 4 263 285 2-s2.0-79751471302
84. Boots A. W., Haenen G. R., Bast A., Health effects of quercetin: from antioxidant to nutraceutical. European Journal of Pharmacology 2008 585 2-3 325 337 2-s2.0-43049176634 10.1016/j.ejphar.2008.03.008
85. Hirpara K. V., Aggarwal P., Mukherjee A. J., Joshi N. J., Burman A. C., Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anti-Cancer Agents in Medicinal Chemistry 2009 9 2 138 161 2-s2.0-64049109356
86. Spagnuolo C., Russo M., Bilotto S., Tedesco I., Laratta B., Russo G. L., Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia. Annals of the New York Academy of Sciences 2012 1259 1 95 103 2-s2.0-84863514720 10.1111/j.1749-6632.2012.06599.x
87. Ossola B., Kaariainen T. M., Mannisto P. T., The multiple faces of quercetin in neuroprotection. Expert Opinion on Drug Safety 2009 8 4 397 409 2-s2.0-67650529189 10.1517/14740330903026944
88. Edwards R. L., Lyon T., Litwin S. E., Rabovsky A., Symons J. D., Jalili T., Quercetin reduces blood pressure in hypertensive subjects. The Journal of Nutrition 2007 137 11 2405 2411 2-s2.0-35848966547
89. Larson A. J., Symons J. D., Jalili T., Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Advances in Nutrition 2012 3 1 39 46 2-s2.0-84862251868
90. Zunino S., Type 2 diabetes and glycemic response to grapes or grape products. The Journal of Nutrition 2009 139 9 1794S 1800S 2-s2.0-69549097608 10.3945/jn.109.107631
91. Hamalainen M., Nieminen R., Vuorela P., Heinonen M., Moilanen E., Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF- B activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF- B activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators of Inflammation 2007 2007 10 2-s2.0-34548562078 10.1155/2007/45673 45673
92. Lee K. W., Kang N. J., Heo Y.-S., Rogozin E. A., Pugliese A., Mun K. H., Bowden G. T., Bode A. M., Hyong J. L., Dong Z., Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Research 2008 68 3 946 955 2-s2.0-38849134933 10.1158/0008-5472.CAN-07-3140
93. Davis J. M., Murphy E. A., McClellan J. L., Carmichael M. D., Gangemi J. D., Quercetin reduces susceptibility to influenza infection following stressful exercise. American Journal of Physiology: Regulatory Integrative and Comparative Physiology 2008 295 2 R505 R509 2-s2.0-51149123497 10.1152/ajpregu.90319.2008
94. Dell'Agli M., Maschi O., Galli G. V., Fagnani R., Dal Cero E., Caruso D., Bosisio E., Inhibition of platelet aggregation by olive oil phenols via cAMP-phosphodiesterase. British Journal of Nutrition 2008 99 5 945 951 2-s2.0-47849102104 10.1017/S0007114507837470
95. Yamashita N., Kawanishi S., Distinct mechanisms of DNA damage in apoptosis induced by quercetin and luteolin. Free Radical Research 2000 33 5 623 633 2-s2.0-0034493221
96. Boly R., Gras T., Lamkami T., Guissou P., Serteyn D., Kiss R., Dubois J., Quercetin inhibits a large panel of kinases implicated in cancer cell biology. International Journal of Oncology 2011 38 3 833 842 2-s2.0-79952033433 10.3892/ijo.2010.890
97. Srivastava A. K., Inhibition of phosphorylase kinase, and tyrosine protein kinase activities by quercetin. Biochemical and Biophysical Research Communications 1985 131 1 1 5 2-s2.0-0022249093
98. Pfeuffer M., Auinger A., Bley U., Kraus-Stojanowic I., Laue C., Winkler P., Rüfer C. E., Frank J., Bösch-Saadatmandi C., Rimbach G., Schrezenmeir J., Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutrition, Metabolism & Cardiovascular Diseases 2013 23 5 403 409 2-s2.0-84876813600 10.1016/j.numecd.2011.08.010
99. Abbey E. L., Rankin J. W., Effect of quercetin supplementation on repeated-sprint performance, xanthine oxidase activity, and inflammation. International Journal of Sport Nutrition and Exercise Metabolism 2011 21 2 91 96 2-s2.0-79955837052
100. Boots A. W., Drent M., de Boer V. C., Bast A., Haenen G. R., Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clinical Nutrition 2011 30 4 506 512 2-s2.0-79960691818 10.1016/j.clnu.2011.01.010
101. Heinz S. A., Henson D. A., Nieman D. C., Austin M. D., Jin F., A 12-week supplementation with quercetin does not affect natural killer cell activity, granulocyte oxidative burst activity or granulocyte phagocytosis in female human subjects. British Journal of Nutrition 2010 104 6 849 857 2-s2.0-77957252267 10.1017/S000711451000156X